Alzheimer preclinical model for the evaluation of
cognitive-enhancing drugs: Memantine validation

Newsletter # 65

Animal models

The NMDA-receptor antagonist Memantine is a FDA-approved drug used to treat Alzheimer-type dementia, especially for patients who have a contraindication to acetylcholinesterase inhibitors. Although clinical evidences support the cognitive-enhancing effect of memantine, the effect in rodents is not very clear yet and results reported so far are not always consistent.

Here we provide a clear-cut result that validate the cognitive enhancing effect of memantine in a rodent model of Alzheimer's disease.

  • Memantine reverses β-amyloid-induced cognitive deficits

  • In this Rat model, cognitive deficit is induced by Intracerebroventricular injection of β-amyloid.

    Treatment with Memantine fully reverses the cognitive deficit.

    This model provides a robust preclinical assay for evaluation of cognitive-enhancing drugs, especially in Alzheimer-type dementia.

NEUROFIT offers a range of validated in vitro and in vivo screening tests for psychiatry and neurology.

If you need further information, please do not hesitate to contact us. Privacy Policy
On a regular basis we distribute newsletters with scientific information on our research services. If you wish to receive these, please sign up on our mailing list: